$248.85
+1.45 (+0.59%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ASND is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 3 observational · 5 with posted results
Held by 12 tracked-famous managers (Artisan Partners Limited Partnership, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, +7 more) · FINRA short interest 7.2 days to cover (settled 2026-07-31) · insider 90d: 7 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and BreastfeedingNCT07345494observationalThe number of fetuses as reported by HCP | — | Recruiting | Drug: Palopegteriparatide | Hypoparathyroidism | 50 | Jan 2036 | ≤ 3,452 d | 2026-03-02 |
| Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersNCT07221851Annualized Height Velocity (AHV) (cm/year)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Combination product: Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector | Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery | 186 | Feb 2028 | ≤ 559 d | 2026-08-19 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaNCT06079398To evaluate the safety and tolerability of NavepegritideRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Navepegritide, Placebo for Navepegritide | Achondroplasia | 72 | Dec 2027 | ≤ 499 d | 2026-04-08 |
| A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.NCT06732895Annualized Growth VelocityRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Navepegritide, Placebo for navepegritide | Achondroplasia | 24 | Aug 2027 | ≤ 377 d | 2026-04-21 |
| A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)NCT07264634observationalTo evaluate the transfer of palopegteriparatide into human breast milk of lactating female participants who are breastfeeding while being treated with YORVIPATH | — | Recruiting | Drug: Palopegteriparatide | Hypoparathyroidism | 10 | Aug 2027 | ≤ 377 d | 2026-08-07 |
| A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismNCT07706764Percentage of participants meeting the multicomponent efficacy endpoint at Week 26Open-label · Treatment | Phase 3 | Recruiting | Combination product: Palopegteriparatide | Hypoparathyroidism | 12 | Aug 2027 | ≤ 377 d | 2026-07-28 |
| TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaNCT05980598Major Pathological ResponseRandomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The Sponsor made the decision to close enrollment as part of a strategic portfolio review. | Drug: TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ | Head and Neck Neoplasms | 27 | 2025-03-28actual | — | 2025-08-01 |
| A Multi-center, Longitudinal, Observational Study of Children With AchondroplasiaNCT03875534observationalAnnualized height velocity (centimeters/year) in children with achondroplasia | — | Completed | — | Achondroplasia | 260 | 2024-01-12actual | — | 2024-03-19 |
| A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialNCT03344458results2024-05-08Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability]Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: TransCon hGH | Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases | 298 | 2023-02-21actual | — | 2026-07-07 |
| A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With AchondroplasiaNCT04085523results2024-03-07Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind TreatmentRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: TransCon CNP, Placebo for TransCon CNP | Achondroplasia | 57 | 2022-09-27actual | — | 2026-07-02 |
| A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismNCT04009291results2023-09-01Efficacy - Primary Endpoint During the Blinded PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Combination product: TransCon PTH, Placebo for TransCon PTH | Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases | 59 | 2020-03-06actual | — | 2026-06-18 |
| Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)NCT01947907results2017-01-19Incidence of Anti-hGH Binding Antibody FormationRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: ACP-001, Human Growth Hormone | Growth Hormone Deficiency (GHD) | 53 | Jul 2015actual | — | 2026-07-08 |
| A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male VolunteersNCT03803163Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · Other | Phase 1 | Terminatedsponsor's stated reason: Discontinued early due to local tolerance expectations not being met. | Drug: TransCon Treprostinil | Healthy Volunteers | 20 | Jun 2015actual | — | 2019-01-14 |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone DeficiencyNCT01247675results2017-03-09Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ACP-001 (TransCon hGH), ACP-001 (TransCon hGH), ACP-001 (TransCon hGH), Omnitrope | Adult Growth Hormone Deficiency | 37 | May 2011actual | — | 2026-07-08 |
| Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)NCT01010425Safety and Tolerability (adverse events, local reactions, immunogenicity)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ACP-001 (TransCon PEG hGH), ACP-001 (TransCon PEG hGH), ACP-001 (TransCon PEG hGH), ACP-001 (TransCon PEG hGH), Placebo, Human Growth Hormone | Healthy | 44 | Feb 2010actual | — | 2010-06-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19